Gene expression profiling analysis of CRTC1-MAML2 fusion oncogene-induced transcriptional program in human mucoepidermoid carcinoma cells

Chen, Jie; Li, Jian-Liang; Chen, Zirong; Griffin, James D.; Wu, Lizi

doi:10.1186/s12885-015-1827-3

Table 1 A subset of CRTC1-MAML2 target gene candidates is shown

From: Gene expression profiling analysis of CRTC1-MAML2 fusion oncogene-induced transcriptional program in human mucoepidermoid carcinoma cells

Gene symbol	Gene title	H3118 Fusion & MAML2 KD/Control	HSY MAML2 KD/Control	Subcelluar localization	Type(s)	Drug(s)	Biomarker application(s)
LINC00473^a	long Intergenlc non-protein coding RNA 473	−37.12	−1.03	Unknown	other
LINC00473^a	long Intergenlc non-protein coding RNA 473	−37.12	−1.03	Plasma	transmembrane
DMBT1^a	deleted in malignant brain tumors 1	−35.73	1.16	Membrane	receptor
DMBT1^a	deleted in malignant brain tumors 1	−35.73	1.16	Membrane	secreted
STC1^a	stanniocalcin 1	−21.74	1.03	Extracellular	glycoprotein		Diagnosis
PDE4B	phosphodiesterase 4B, cAMP-specific	−8.41	1.09	Cytoplasm	enzyme	dyphylline, nitroglycerin
PDE4B	phosphodiesterase 4B, cAMP-specific	−8.41	1.09	Cytoplasm	transcription	dyphylline, nitroglycerin
RUNX3	runt-related transcription factor 3	−4.88	1.03	Nucleus	regulator		Diagnosis
RUNX3	runt-related transcription factor 3	−4.88	1.03	Nucleus	regulator		Prognosis
PTGS1^a	prostaglandin-endoperoxide synthase 1	−3.89	1.31	Cytoplasm	enzyme	acetaminophen, aspirin	Progression
PTGS1^a	prostaglandin-endoperoxide synthase 1	−3.89	1.31	Cytoplasm	enzyme	acetaminophen, aspirin	Prognosis
PDE4D	phosphodiesterase 4D, cAMP-specific	−2.93	1.05	Cytoplasm	enzyme	dyphylline, nitroglycerin	Prognosis
							Diagnosis
							Efficacy
CA9^a	carbonic anhydrase IX	−2.77	1.2	Nucleus	enzyme	CG250, Methazolamide Tazarotene	Prognosis
CA9^a	carbonic anhydrase IX	−2.77	1.2	Nucleus	enzyme	CG250, Methazolamide Tazarotene	Diagnosis
ODC1	ornithine decarboxylase 1	−2.54	−1.06	Cytoplasm	enzyme	Eflornithine	Efficacy
ODC1	ornithine decarboxylase 1	−2.54	−1.06	Cytoplasm	enzyme	AP-12009	Efficacy
TGFB2^a	transforming growth factor, beta 2	−2.48	1.21	Extracellular	growth factor	Lerdelimumab	Efficacy
TGFB2^a	transforming growth factor, beta 2	−2.48	1.21	Extracellular	growth factor	Lerdelimumab	Diagnosis
AREG^a	Amphiregulin	−2.23	1.11	Extracellular	growth factor	Cetuximab, gefitinib	Efficacy
AREG^a	Amphiregulin	−2.23	1.11	Extracellular	growth factor	Cetuximab, gefitinib	Prognosis
TYMS^a	thymidylate synthetase	−2.1	−1.03	Nucleus	enzyme	Flucytosine, 5-fluorouracil	Diagnosis
							Efficacy
							Prognosis
CDK6	cvclin-deDendent kinase 6	−2.07	1.02	Nucleus	kinase	PD-0332991	Proanosis
CDK6	cvclin-deDendent kinase 6	−2.07	1.02	Nucleus	kinase	flavopiridol	Proanosis

The fold changes of gene expression were shown for fusion-positive MEC H3118 cells with fusion/MAML2 knockdown (KD), and fusion-negative HSY cells with MAML2 KD
^a Genes down-regulated in H3118 cells with CREB KD

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us